Zobrazeno 1 - 10
of 45
pro vyhledávání: '"STRAIL FUSION PROTEIN"'
Autor:
Yunwei Wei, Valerie R. Wiersma, Marloes J. M. Gooden, Wijnand Helfrich, Djoke Hendriks, Hans W. Nijman, Douwe F. Samplonius, Jin Zhou, Maartje C.A. Wouters, Marco de Bruyn, Ce Shi, Edwin Bremer
Publikováno v:
mAbs, 7(2), 321-330
The therapeutic effect of anti-cancer monoclonal antibodies stems from their capacity to opsonize targeted cancer cells with subsequent phagocytic removal, induction of antibody-dependent cell-mediated cytotoxicity (ADCC) or induction of complement-m
Publikováno v:
Journal of gene medicine. 16(9-10):281-290
BackgroundProgressive liver fibrosis is the result of chronic liver injury and is characterized by the excessive accumulation of extracellular matrix that may result in liver failure. Activated hepatic stellate cells are known to play a central role
Publikováno v:
Biochimica et Biophysica Acta-Biomembranes. 1828(8):1989-2001
Injection of tumor cells in mice more than 30 years ago resulted in the discovery of an epithelial antigen, later defined as a cell adhesion molecule (EpCAM). Although EpCAM has since evoked significant interest as a target in cancer therapy, mechani
Autor:
Valerie R. Wiersma, Wijnand Helfrich, R.J. van Ginkel, Yuan He, Djoke Hendriks, Iris Koopmans, Edwin Bremer, Douwe F. Samplonius
Publikováno v:
OncoImmunology, 5(8):1202390. Taylor & Francis Group
Oncoimmunology
Oncoimmunology
Antibodies that block PD-L1/PD-1 immune checkpoints restore the activity of functionally-impaired antitumor T cells. These antibodies show unprecedented clinical benefit in various advanced cancers, particularly in melanoma. However, only a subset of
Publikováno v:
CURRENT DRUG TARGETS. 11(1):95-110
Despite recent advances, treatment of leukemia is often not curative. New insights indicate that this may be attributable to a small population of therapy-resistant malignant cells with self-renewal capacity and the ability to generate large numbers
Publikováno v:
CURRENT DRUG TARGETS. 10(2):94-103
Antibody-based therapeutic approaches are yielding more and more of the promise they have held since the conception of the 'magic bullet' theory by Paul Ehrlich. The beneficial effect of antibody-based therapies is directly related to antibody-depend
Publikováno v:
Apoptosis. 13(2):225-235
Recombinant TNF-related apoptosis-inducing ligand (TRAIL) is considered a powerful and selective inducer of tumor cell death. We hypothesize that TRAIL's potential as anticancer agent can be enhanced further by promoting its accumulation in tumor tis
Publikováno v:
TRENDS IN MOLECULAR MEDICINE. 12(8):382-393
Important breakthroughs in cancer therapy include clinical application of antibodies, such as Rituximab, and small inhibitory molecules, such as Iressa and Velcade. In addition, recent reports have indicated the therapeutic potential of physiological
Publikováno v:
Blood, 107(7), 2863-2870. AMER SOC HEMATOLOGY
Agonistic anti-Fas antibodies and multimeric recombinant Fas ligand (FasL) preparations show high tumoricidal activity against leukemic cells, but are unsuitable for clinical application due to unacceptable systemic toxicity. Consequently, new antile
Publikováno v:
Journal of gene medicine, 16(9-10), 281-290. Wiley
BackgroundProgressive liver fibrosis is the result of chronic liver injury and is characterized by the excessive accumulation of extracellular matrix that may result in liver failure. Activated hepatic stellate cells are known to play a central role
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=narcis______::f96db6ced0de9747532fe8c9dfaf5268
https://research.rug.nl/en/publications/6e8ee927-a848-4530-b8f4-f7a36312bf68
https://research.rug.nl/en/publications/6e8ee927-a848-4530-b8f4-f7a36312bf68